We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock
FRTX

Delisted

FRTX was delisted on the 18th of December, 2023.

Back to rankings

30 hedge funds and large institutions have $9.25M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

15,800% more call options, than puts

Call options by funds: $159K | Put options by funds: $1K

167% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 3

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

11% more funds holding

Funds holding: 27 → 30 (+3)

23% less capital invested

Capital invested by funds: $12M → $9.25M (-$2.76M)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
8
Reduced
3
Closed
3
Calls
$159K
Puts
$1K
Net Calls
+$158K
Net Calls Change
+$65K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$1.06M
2
Renaissance Technologies
Renaissance Technologies
New York
+$600K
3
Deutsche Bank
Deutsche Bank
Germany
+$242K
4
VF
Virtu Financial
New York
+$129K
5
ARTA
A.R.T. Advisors
New York
+$46.9K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$5.14M
2
JP Morgan Chase
JP Morgan Chase
New York
-$103K
3
BCM
Bridgeway Capital Management
Texas
-$56.3K
4
Macquarie Group
Macquarie Group
Australia
-$8K
5
BlackRock
BlackRock
New York
-$3.35K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$2.73M +$1.06M +3,153 +77%
SCM
2
Sio Capital Management
New York
$1.94M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$1.92M +$600K +1,791 +55%
Vanguard Group
4
Vanguard Group
Pennsylvania
$692K -$2.68K -8 -0.4%
BlackRock
5
BlackRock
New York
$472K -$3.35K -10 -0.8%
Deutsche Bank
6
Deutsche Bank
Germany
$272K +$242K +721 New
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$263K +$43.6K +130 +23%
PAM
8
Panagora Asset Management
Massachusetts
$196K – – –
VF
9
Virtu Financial
New York
$146K +$129K +386 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$134K – – –
CC
11
Clearline Capital
New York
$90K +$335 +1 +0.4%
Citadel Advisors
12
Citadel Advisors
Florida
$56K +$21.1K +63 +73%
ARTA
13
A.R.T. Advisors
New York
$53K +$46.9K +140 New
BCM
14
Bridgeway Capital Management
Texas
$42K -$56.3K -168 -60%
California Public Employees Retirement System
15
California Public Employees Retirement System
California
$37K – – –
Two Sigma Investments
16
Two Sigma Investments
New York
$37K – – –
Northern Trust
17
Northern Trust
Illinois
$34K – – –
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$28K +$5.03K +15 +25%
SPIA
19
Steward Partners Investment Advisory
New York
$20K – – –
Morgan Stanley
20
Morgan Stanley
New York
$17K +$14.1K +42 +1,050%
RC
21
RBF Capital
California
$16K – – –
Bank of America
22
Bank of America
North Carolina
$15K – – –
UBS Group
23
UBS Group
Switzerland
$15K +$12.4K +37 +1,850%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$14K – – –
Simplex Trading
25
Simplex Trading
Illinois
$4K +$4.36K +13 New
1
2

FRTX Hedge Fund Activity: Q1 2019 in Review

30 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2019, worth a combined $9.25M — down 23% from $12M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new FRTX positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 3 trimmed.

The largest buyer was BVF Inc, adding an estimated $1.06M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.14M sold.

  • 30 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2019, up from 27 in Q4 2018.
  • Funds reported $9.25M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2019, down 23% quarter-over-quarter.
  • 6 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2019 and 3 closed out, a net change of +3 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2019 was BVF Inc, an estimated $1.06M added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2019 was Armistice Capital, an estimated $5.14M sold.

Based on aggregated 13F filings for Q1 2019.